INOVIO Pharmaceuticals Unveils $20 Million Public Offering Pricing

On July 29, 2026, INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company renowned for its focus on DNA medicines aimed at combating HPV-related diseases, cancer, and infectious diseases, announced the pricing details of its latest public offering. The company is offering 21,052,632 shares of its common stock, along with warrants to purchase up to 42,105,264 additional shares of common stock.

The public offering price has been set at $0.95 per share, which includes a warrant allowing purchase of two shares per unit at an exercise price of $1.10 per share. Moreover, the underwriter has been granted an option for 30 days to purchase additional shares and warrants, amounting to up to 3,157,894 shares. This option represents a strategic move to leverage potential investor interest and raise additional funds if market conditions are favorable.

The anticipated gross proceeds from this offering are expected to reach approximately $20 million, before deducting the underwriting discounts, commissions, and any other offering-related expenses. This funding is crucial for INOVIO as it ventures further into the development of its cutting-edge DNA medicines.

Key Developments Leading Up to the Offering

This public offering comes on the heels of INOVIO’s ongoing commitment to fight HPV-related diseases, a major public health concern globally. The company has previously established a solid track record of innovation in the biotech sector. INOVIO’s technology focuses on optimizing the design and delivery of DNA medicines that instruct the body to produce its own disease-fighting proteins, setting the groundwork for potentially groundbreaking treatments in the future.

Role of Piper Sandler

Piper Sandler has been designated as the sole manager for this offering, guiding INOVIO through the intricate process of raising funds while ensuring compliance with regulatory requirements. A shelf registration statement for the public offering of shares was filed with the Securities and Exchange Commission (SEC) on July 2, 2026, and received approval shortly thereafter on July 10, 2026.

Important Dates and Considerations

The closing date for this public offering is anticipated to occur on or about July 31, 2026, contingent upon the fulfillment of customary closing conditions. It is crucial to note that this news release does not constitute an offer to sell or solicit an offer to buy securities in any region where such action would be unlawful before the necessary registrations or qualifications.

Conclusion

INOVIO’s proactive steps to secure funding reflect its dedication to tackling significant health challenges through innovative biotechnology solutions. The successful pricing of the public offering signals robust market confidence and underlines the increasing role of biotechnology firms in healthcare. As the landscape of medical technology continues to evolve, INOVIO positions itself as a formidable player in the fight against HPV-related diseases and beyond. Investors and stakeholders will be keeping a close eye on the developments following this strategic offering as INOVIO embarks on its next chapter in biopharmaceutical advancements.